The drug at the center of the resistance story is ABT-737, a synthetic small molecule that belongs to the BH3-mimetic family. These compounds mimic a short protein segment, the Bcl-2 homology 3 domain, that pro-apoptotic proteins use to latch onto and neutralize their anti-apoptotic relatives. In healthy cells, the Bcl-2 protein family functions as a molecular checkpoint for apoptosis, the programmed self-destruction pathway that eliminates damaged or superfluous cells. The family contains pro-death effectors such as Bak and Bax, which punch holes in the outer mitochondrial membrane to trigger the apoptotic cascade, and anti-apoptotic guardians such as Bcl-2, Bcl-xL, and myeloid cell leukemia-1, or Mcl-1, which sequester those effectors and keep the checkpoint locked. BH3 mimetics pry that lock open. ABT-737 binds Bcl-2, Bcl-w, and Bcl-xL with high affinity, freeing Bak and Bax to initiate mitochondrial outer membrane permeabilization and release cytochrome c.

The fatal flaw of ABT-737, documented repeatedly since its 2005 debut in Nature, is what it cannot bind. Mcl-1 sits outside its reach, and cancer cells respond to Bcl-2 family pressure by leaning harder on Mcl-1 for survival. Prior work has shown that breast cancer cells frequently increase Mcl-1 expression when exposed to ABT-737, and that the drug performs dramatically better in cell lines where Mcl-1 is degraded or genetically silenced. In triple-negative breast cancer specifically, dependence on Mcl-1 has been traced to its canonical anti-apoptotic function, making the protein both a vulnerability and the principal escape route from Bcl-2-targeted therapy. Clinical efforts to develop selective Mcl-1 inhibitors have been beset by cardiac toxicity concerns, which has pushed researchers toward indirect strategies that lower Mcl-1 levels using existing or better-tolerated compounds.

Enter C-phycocyanin, the phycobiliprotein pigment that gives spirulina and other cyanobacteria their distinctive blue-green color. It is not an obscure molecule. Phycocyanin is consumed as a dietary supplement, has been investigated as a natural anti-inflammatory and antioxidant, and has accumulated a growing preclinical dossier of anti-cancer activity across breast, pancreatic, and gastrointestinal tumor models. Earlier studies in triple-negative breast cancer cells, including the aggressive MDA-MB-231 line, showed that the pigment suppresses proliferation and migration through the MAPK signaling pathway. What the new study adds is a precise mechanistic account of how C-phycocyanin interacts with the Bcl-2 family to convert ABT-737 from a partially effective drug into a synergistic killer.

The experimental system was deceptively simple. Shayesteh Khishavand and Hadi Karami cultured MDA-MB-468 cells, a well-characterized triple-negative breast cancer line that carries mutant p53 and an epidermal growth factor receptor amplification, and treated them with C-phycocyanin alone, ABT-737 alone, or the two drugs in combination. They then measured cell viability with MTT assays, proliferation with trypan blue exclusion, migratory capacity with wound healing assays, long-term reproductive survival with clonogenic assays, apoptosis with ELISA-based detection, and caspase-3 enzymatic activity. Expression of the key Bcl-2 family players was quantified at both the messenger RNA level by quantitative reverse transcription PCR and the protein level by Western blot. Drug interactions were formally assessed using the Combination Index method, a widely used framework in which values below one indicate synergy, values near one indicate additivity, and values above one indicate antagonism.

The numbers tell a striking story. On its own, C-phycocyanin inhibited half of the cells at a concentration of 5.62 micromolar, while ABT-737 required 32.47 micromolar to reach the same effect, reflecting the substantial intrinsic resistance of these cells to the BH3 mimetic. When the two agents were combined, the half-maximal inhibitory concentration of the drugs dropped to 3.71 micromolar, and the Combination Index fell below one, formally confirming a synergistic interaction. In practical terms, each drug needed less of itself to do more damage when partnered with the other, exactly the pharmacological profile that combination therapy seeks.

The molecular mechanism underlying that synergy resolved into a familiar pattern of compensatory resistance and its circumvention. When ABT-737 was applied alone, MDA-MB-468 cells raised Mcl-1 expression by roughly 40 percent, a textbook survival response to pressure on the Bcl-2 branch of the family. C-phycocyanin co-treatment effectively counteracted that response, holding Mcl-1 in check. Beyond blunting the adaptive Mcl-1 surge, the pigment also downregulated Bcl-2 itself while simultaneously increasing expression of Bak, the pro-apoptotic effector that ABT-737 liberates, and p53, the tumor suppressor that coordinates apoptotic responses to cellular stress. The net effect was to strip away the anti-apoptotic shielding while boosting the pro-apoptotic force, tilting the Bcl-2 family balance decisively toward mitochondrial breach.

Downstream readouts confirmed that the shift translated into genuine cell death and functional impairment. The combination produced significantly greater caspase-3 activation than either drug alone, indicating that the intrinsic apoptotic cascade had been engaged to completion. Apoptosis measured by ELISA rose in parallel. The partnership also constrained malignant behavior beyond the dish-level kill: cells treated with both drugs migrated far less effectively in wound healing assays and formed markedly fewer colonies, suggesting that the combination impairs both dissemination potential and the self-renewal capacity required for tumor propagation, not merely acute viability.

The authors are appropriately measured about the scope of their findings. The work rests on a single cell line, and MDA-MB-468, with its mutant p53 and EGFR amplification, represents only one molecular identity within the heterogeneous universe of triple-negative breast cancer. The study itself notes that further validation in additional triple-negative cell lines is warranted, and the jump from two-dimensional cultures to animal models and, ultimately, patients remains long and uncertain. C-phycocyanin’s pharmacokinetics, bioavailability, and safety profile at efficacious doses in humans are not established by this work, and ABT-737 itself was succeeded clinically by orally bioavailable derivatives such as navitoclax and venetoclax, which carry their own resistance and toxicity profiles.

Even with those caveats, the study lands at a moment of genuine momentum for apoptosis-targeted cancer therapy. The conceptual advance is that a well-tolerated natural product, rather than a bespoke synthetic Mcl-1 inhibitor, can suppress the compensatory pathway that limits BH3-mimetic efficacy, opening a lower-toxicity route to rational combination design. It also reinforces a principle that has emerged across multiple tumor types: the predictive value of Mcl-1 levels for BH3-mimetic response, and the therapeutic value of manipulating those levels directly. Whether C-phycocyanin can make that leap from pigment to pharmaceutical partner will depend on the validation studies that must now follow, but for a cancer with so few molecular handles, the identification of a new one, plucked from a common blue-green alga, is a result worth watching closely.

Subject of Research: Overcoming ABT-737 resistance in triple-negative breast cancer through C-phycocyanin-mediated Mcl-1 downregulation

Article Title: Overcoming ABT-737 resistance in triple-negative breast cancer: C-phycocyanin-mediated myeloid cell leukemia-1 downregulation enhances apoptotic sensitivity

Article References: Khishavand, S., & Karami, H. (2026). Overcoming ABT-737 resistance in triple-negative breast cancer: C-phycocyanin-mediated myeloid cell leukemia-1 downregulation enhances apoptotic sensitivity. Molecular Biology Reports, 53(1), Article 1614. https://doi.org/10.1007/s11033-026-12824-5

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12824-5

Keywords: triple-negative breast cancer, ABT-737, C-phycocyanin, Mcl-1, BH3 mimetics, apoptosis, drug synergy, Bcl-2 family, combination therapy, MDA-MB-468, caspase-3, natural products

To understand why this matters, it helps to look at how bladder cancer is treated today. When the tumor invades the muscle wall of the bladder, the standard of care typically involves radical surgery, often accompanied by perioperative chemotherapy built around cisplatin. That platinum-based drug damages DNA in rapidly dividing cells, triggering a cascade that should end in cell death. Yet in practice, many tumors either fail to respond from the outset or acquire resistance over time, and cisplatin’s significant side effects limit how much patients can tolerate. The result is a therapeutic window that is narrow on both ends: not enough killing power against resistant cells, and too much collateral damage to healthy tissue. Improving the efficiency of cisplatin, so that lower or standard doses achieve deeper tumor responses, is therefore a major goal in urothelial cancer research.

The Seville team focused their attention on a family of proteins that cancer cells exploit to stay alive: the antiapoptotic members of the Bcl-2 family. In healthy tissue, the Bcl-2 protein family acts as a molecular switchboard controlling apoptosis, the programmed self-destruction process that eliminates damaged or unwanted cells. Pro-apoptotic members of the family push the cell toward death by permeabilizing the outer mitochondrial membrane, while antiapoptotic members such as Bcl-2, Bcl-xL and Mcl-1 bind and neutralize those death-promoting proteins, keeping the switch in the off position. Many cancers overproduce these antiapoptotic guardians, effectively locking the apoptotic machinery shut. This not only supports tumor growth but also shields malignant cells from chemotherapy, since drugs like cisplatin rely heavily on apoptosis to finish the job they start with DNA damage.

Enter BH3 mimetics, an emerging class of targeted drugs designed to reverse exactly this blockade. These molecules mimic the BH3 domain, the short alpha-helical segment that pro-apoptotic proteins use to dock onto their antiapoptotic counterparts. By occupying the binding grooves of proteins like Bcl-2, Bcl-xL and Mcl-1, BH3 mimetics pry the molecular lock open, freeing the death effectors to do their work. The strategy has already produced approved therapies in blood cancers, and researchers worldwide are racing to extend it to solid tumors. In the new study, the Spanish team tested two such compounds: ABT-737, a well-characterized antagonist of Bcl-2, Bcl-w and Bcl-xL, and obatoclax, a broader-spectrum pan-BH3 mimetic that also targets Mcl-1.

The experimental system centered on two human bladder cancer cell lines, HT1197 and HT1376, chosen to represent the aggressive urothelial tumors the therapy would ultimately need to defeat. The researchers treated these cells with each BH3 mimetic alone, with cisplatin alone, and with the drugs in combination, then measured cell viability, apoptosis and autophagy using standard laboratory assays. The results were striking. Combining ABT-737 and obatoclax produced a dramatic decrease in cell viability and a marked increase in apoptosis, indicating that hitting the antiapoptotic network from multiple angles at once overwhelms the survival machinery of the cancer cells. More importantly for the clinical question at hand, ABT-737 sensitized HT1197 cells to cisplatin, while obatoclax performed the same sensitizing role in HT1376 cells, allowing the platinum drug to kill tumor cells that would otherwise have survived.

A key strength of the study lies in the models used to confirm the effect. Two-dimensional cell cultures are convenient but notoriously poor predictors of how tumors behave in patients, so the team extended their work to three-dimensional spheroids, including tumorspheres derived from the same HT1197 and HT1376 lines and, critically, spheroids grown directly from bladder cancer patients. These patient-derived spheroids preserve much of the architecture and heterogeneity of real tumors, making them a far more faithful testing ground. The sensitizing effect of the BH3 mimetics held up in these more demanding models, strengthening the case that the phenomenon is not an artifact of simplified laboratory conditions but a genuine vulnerability of bladder cancer cells.

The study also dug into the mechanism behind the sensitization, and here the story takes an intriguing turn involving autophagy, the cellular recycling process that cells use to survive stress. Autophagy can act as a double-edged sword in cancer: in some contexts it suppresses tumors, but in established cancers it often serves as a survival pathway, feeding cells through nutrient scarcity and buffering them against chemotherapy-induced damage. The researchers discovered that combined treatment with cisplatin and obatoclax potentiates the blockade of autophagic flux in HT1376 cells, meaning the recycling machinery jams rather than merely slowing down. Blocked autophagic flux is toxic to cells, and its disruption in this setting pushes the tumor cells closer to the apoptotic brink.

What connects cisplatin, obatoclax and the autophagy machinery is an unexpected protein partnership. Using immunoprecipitation and immunofluorescence techniques in the HT1197 and HT1376 lines, the team examined the interaction between Mcl-1, the antiapoptotic Bcl-2 family member, and beclin-1, a central regulator of autophagy initiation. Their experiments showed that the combined treatment disrupts the interaction between Mcl-1 and beclin-1 in HT1376 cells. This finding suggests that Mcl-1 does more than simply block apoptosis; by binding beclin-1 it also appears to participate in the control of autophagy, and when obatoclax and cisplatin interfere with that interaction, the tumor cell loses both a survival pathway and its autophagic escape route simultaneously. The convergence of these two stresses, failed autophagy and unleashed apoptosis, offers a mechanistic explanation for why the drug combination is so much more lethal than either agent alone.

Beyond the mechanistic work, the study provides a clinically relevant translational anchor. The researchers used immunohistochemistry to evaluate the expression of Bcl-xL and Mcl-1 proteins in tissue samples from a series of muscle-invasive bladder tumors. The result was sobering but encouraging: more than half of the analyzed tumors expressed either Bcl-xL or Mcl-1. In other words, the molecular targets that the BH3 mimetics attack are not rare curiosities but common features of the very tumors that urological oncologists treat every day. That prevalence matters, because it hints at a potential biomarker strategy: patients whose tumors overexpress Bcl-xL might be matched with ABT-737-like agents alongside cisplatin, while those with Mcl-1-high tumors might receive obatoclax-based combinations. Such stratification is exactly the kind of precision-oncology approach that has transformed treatment in other cancer types.

As with any preclinical study, important caveats remain before this science can reach the clinic. ABT-737 is a research tool rather than an approved drug, and its clinical descendant navitoclax has been limited by effects on blood platelets, while obatoclax has faced its own challenges in clinical trials. The current findings establish the principle and the mechanism in cell lines and spheroids, but animal studies and ultimately clinical trials would be needed to confirm safety and efficacy in patients. Nevertheless, the work from the Seville group, conducted with support from Spanish national funding and the Andalusian health system’s biobank network, lays out a coherent and testable path forward. For patients with muscle-invasive bladder cancer, a disease in which cisplatin resistance and toxicity remain life-limiting obstacles, the message is one of cautious optimism: the molecular shields that tumors use to survive chemotherapy can be identified, targeted and dismantled, and when they fall, the old workhorse drug cisplatin may regain its killing power.

Subject of Research: BH3 mimetic drugs as sensitizers of cisplatin chemotherapy in muscle-invasive bladder cancer

Article Title: BH3 mimetics sensitize bladder cancer cells to cisplatin treatment

Article References: González-Moreno, M., Jiménez-Guerrero, R., Pérez-Valderrama, B., Medina, R. A., Rivero-Belenchón, I., Lendinez-Cano, G., Romero, F., Japón, M. Á., & Sáez, C. (2026). BH3 mimetics sensitize bladder cancer cells to cisplatin treatment. Cancer Cell International. https://doi.org/10.1186/s12935-026-04473-2

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04473-2

Keywords: bladder cancer, BH3 mimetics, cisplatin, Bcl-2 family, Mcl-1, Bcl-xL, apoptosis, autophagy, beclin-1, chemotherapy resistance, obatoclax, ABT-737